Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
November 1, 2022
Assignee:
Valneva SE
Inventors:
Andrea Fritzer, Andreas Meinke, Urban Lunberg, Mario Nebenfuhr, Jurgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
Type:
Grant
Filed:
August 19, 2021
Date of Patent:
October 25, 2022
Assignees:
Valneva Austria GmbH, Valneva USA, Inc.
Inventors:
Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
October 11, 2022
Assignee:
Valneva Austria GmbH
Inventors:
Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
Abstract: The present invention relates to a single-shot live attenuated vaccine against Chikungunya virus which is well-tolerated and induces long-lasting protective immunity in adult human subjects.
Abstract: The present invention is related to novel liquid and lyophilized formulations of Chikungunya virus useful as vaccines and methods for their preparation.
Type:
Application
Filed:
August 10, 2020
Publication date:
September 15, 2022
Applicant:
Valneva SE
Inventors:
Christoph Reinisch, Robert Schlegl, Jürgen Heindl-Wruss
Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Type:
Application
Filed:
December 13, 2021
Publication date:
September 1, 2022
Applicant:
Valneva Austria GmbH
Inventors:
Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
Abstract: The present invention relates to modified metapneumovirus (hMPV) F proteins, stabilized in the pre-fusion conformation. It also relates to immunogenic compositions (vaccines) comprising these proteins for preventing and/or treating human subjects against respiratory tract infections.
Type:
Application
Filed:
May 19, 2020
Publication date:
June 16, 2022
Applicant:
Valneva SE
Inventors:
Fabien Perugi, Klaus Schwamborn, Wolfgang Schüler, Urban Lundberg, Andreas Meinke
Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
Type:
Application
Filed:
November 2, 2021
Publication date:
June 16, 2022
Applicant:
Valneva Austria GmbH
Inventors:
Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
Abstract: This present invention provides C-TAB.G5 and C-TAB.G5.1 isolated polypeptides comprising the receptor binding domains of C. difficile toxin A and toxin B as set forth in the amino acid sequences of SEQ ID NO: 2 and SEQ ID NO: 4. The C-TAB.G5 and C-TAB.G5.1 isolated polypeptides may be used to neutralize toxic effects of C. difficile toxin A and/or toxin B.
Type:
Grant
Filed:
October 2, 2020
Date of Patent:
June 14, 2022
Assignees:
Valneva Austria GmbH, Valneva USA, Inc.
Inventors:
Larry R. Ellingsworth, David Flyer, Jing-Hui Tian, Steven R. Fuhrmann, Stefanie Kluepfel-Stahl, Gregory M. Glenn, Kerstin Westritschnig
Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
August 20, 2021
Date of Patent:
June 14, 2022
Assignee:
Valneva SE
Inventors:
Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schiegl, Arnaud Leon
Abstract: Described herein are improved purification methods for Zika virus vaccines and compositions. Also described are Zika vaccines and methods of producing and administering said Zika vaccines to subjects in need thereof.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
May 17, 2022
Assignee:
Valneva Austria GmbH
Inventors:
Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
Type:
Application
Filed:
August 4, 2021
Publication date:
April 28, 2022
Applicant:
Valneva Austria GmbH
Inventors:
Robert Schlegl, Michael Möhlen, Jürgen Heindl-Wruss, Michael Weber
Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
Type:
Application
Filed:
August 20, 2021
Publication date:
January 20, 2022
Applicant:
Valneva SE
Inventors:
Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schlegl, Arnaud Leon
Abstract: Described herein are Zika virus vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.
Type:
Grant
Filed:
March 10, 2020
Date of Patent:
January 11, 2022
Assignee:
Valneva Austria GmbH
Inventors:
Jana Barbero Calzado, Mario Nebenführ, Robert Schlegl, Michael Weber, Jürgen Heindl-Wruss
Abstract: Described herein are improved purification methods for virus vaccines and compositions. Also described are Zika, Chikungunya, dengue and yellow fever vaccines and methods of producing and administering said vaccines to subjects in need thereof.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
December 28, 2021
Assignee:
Valneva SE
Inventors:
Jana Barbero Calzado, Mario Nebenführ, Robert Schiegl, Michael Weber, Jürgen Heindl-Wruss
Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
Type:
Grant
Filed:
February 27, 2018
Date of Patent:
December 28, 2021
Assignee:
Valneva Austria GmbH
Inventors:
Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schüler, Benjamin Wizel
Abstract: The present invention relates to methods of rescue and/or propagation of paramyxovirus species, particularly wherein both rescue and propagation are carried out in the same cell type; i.e., without the use of helper cells for viral rescue. The paramyxoviruses produced by the disclosed methods may encompass wild-type viruses, chimeric viruses, recombinant viruses or engineered viral products such as virus like particles (VLP). Viruses and/or viral products produced in the method according to the current invention are suitable for medical or veterinary use in such applications as treating or preventing infectious diseases, particularly avian paramyxovirus and human respiratory virus infections, and cancer treatment.
Type:
Application
Filed:
July 15, 2019
Publication date:
September 9, 2021
Applicant:
Valneva SE
Inventors:
Luc Batard, Caroline Freslon-Evain, Fabien Perugi, Klaus Schwamborn
Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
Type:
Grant
Filed:
January 6, 2020
Date of Patent:
September 7, 2021
Assignee:
Valneva Austria GmbH
Inventors:
Robert Schlegl, Michael Möhlen, Jürgen Heindl-Wruss, Michael Weber